MMJ's CEO Jason Conroy commented that "A strong rebound over the past few weeks in the share prices of our public company investments (Harvest One and MediPharm Labs) has increased our post-tax NTA to approximately 27 cents per share as at 12 January 2019. We are very pleased with this improving performance and look forward to announcing further progress and developments across our portfolio in the coming months."

* The pre and post-tax numbers relate to the provision for deferred tax on the unrealised gains in MMJ's investment portfolio. Under current Accounting Standards, MMJ is required to provide for tax on any gains that may arise on such a theoretical disposal, after the utilisation of brought forward losses.